Quest Magazine

DMD: Drisapersen Receives ‘Breakthrough Therapy’ Designation

Multinational pharmaceutical company GlaxoSmithKline (GSK) has announced that its experimental Duchenne muscular dystrophy (DMD) drug drisapersen has received breakthrough therapy designation from the U.S. Food and Drug Administration.

A ‘Transport Problem’ May Cause Motor Neuron Death

Axonal transport is the process that is responsible for moving nutrients, proteins and other vital cellular cargo to and from the cell bodies in motor neurons – the muscle-controlling nerve cells that are lost in amyotrophic lateral sclerosis (ALS).

New Muscular Dystrophy Drugs Offer Hope

26th Annual MDA Ride for Life Breaks $1 Million Mark to Help Fight Muscle Disease

DMD UPDATE: Drisapersen Outperforms Placebo in Walking Test

Lowe's Raises $8.8 Million for MDA's Shamrocks Campaign

MDA Scientific Conference Blog: Playing in the Same Sandbox

MDA Scientific Conference Blog: We Need Each Other

MDA Scientific Conference Blog: Gracious Professionalism and ‘Coopertition’

MDA Scientific Conference Blog: First Things First: The Necessity and Challenges of Mouse Models

Pages